Introduction: Laparoscopic liver resection (LLR) has revolutionized liver surgery by offering several advantages over traditional open procedures. However, conventional LLR (C-LLR) has certain limitations, such as the inability to palpate tumors and the need for continuous ultrasound guidance during surgery, which can result in complications. Real-time tumor-tracking technologies, such as indocyanine green (ICG) fluorescence imaging, have shown potential in enhancing tumor detection and improving perioperative outcomes. The Liver-Light study aims to evaluate the feasibility of integrating ICG fluorescence with 4 K imaging technology during LLR (ICG4K-LLR) to improve postoperative surgical and oncological outcomes.
Methods: This study is a prospective, single-center investigation that included 42 patients who underwent ICG4K-LLR. These patients were matched in a 1:1 ratio using propensity scores with patients from retrospective data who underwent C-LLR. Potential confounding factors, including sex, age, body mass index, tumor type, and the complexity of LLR, were selected for matching. Postoperative surgical and oncological outcomes were then compared between the two groups.
Results: After propensity score-matched analysis, the ICG4K-LLR group demonstrated several significant advantages over the C-LLR group. Operation times were shorter in the ICG4K-LLR group (155.2 min vs. 196.6 min, p = 0.002), with reduced blood loss (300.0 ml vs. 501.2 ml, p = 0.006) and fewer blood transfusions (0% vs. 14.3%, p = 0.011). Additionally, no patients in the ICG4K-LLR group had positive resection margins, whereas 14.3% of patients in the C-LLR group did (p = 0.011). The incidence of clinically relevant posthepatectomy liver failure (p = 0.040) and major morbidity (p = 0.035) was significantly lower in the ICG4K-LLR group. Furthermore, the 1-year disease free survival rate was significantly higher in the ICG4K-LLR group (92.3% vs. 64.3%, p = 0.004).
Conclusion: ICG4K-LLR has a promising potential as a safe and effective navigation system, offering improved perioperative surgical and oncological outcomes compared to C-LLR.
